Compare DexCom, Inc. (DXCM) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Target Corporation — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Target Corporation trades at $153.77 (market cap $70.31B). The key difference: Target Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and Target Corporation pays a 3% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Target Corporation for 137 Days on average.
| DXCM | TGT | |
|---|---|---|
Market Cap | $31.86B | $70.31B |
Volume | 3,607,070 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $169.90 |
52-Week Low | $54.84 | $83.68 |
Typical Hold Time | 62 Days | 137 Days |
Enterprise Value | $31.32B | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Target Corporation (TGT) trades at $154.76, up 2.52% with strong recent earnings beats. The stock shows bearish technical signals but maintains solid fundamentals with a 26.41% ROE and 4.08% net margin. Recent price cuts on 2,000 items aim to capture holiday market share, while analyst consensus targets $167.18 with 47% buy ratings. Cash flow remains positive at $957M despite competitive retail pressures.
Target presents a mixed outlook with valuation appeal (P/E 16.05) against bearish technicals. Upside potential exists from continued earnings outperformance and dividend stability, but risks include margin pressure from price investments and weak consumer spending. The stock offers value for patient investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
